AI Article Synopsis
- IgE-mediated food allergies cause significant emotional and financial strain on affected individuals and their families, with the risk of severe allergic reactions.
- Traditionally, management involved avoiding allergens and treating reactions as they occur, but new treatments are emerging.
- Omalizumab has been approved for preventing serious allergic reactions in both adults and children over one year, and may work well with oral immunotherapy; other biologics and inhibitors are also showing promise in this area.
Article Abstract
Immunoglobuin E (IgE)-mediated food allergies greatly impact patients and their families, causing financial and emotional stress, and placing them at risk for lifethreatening reactions. Until recently, food allergies have been treated with allergen avoidance and emergency treatment of allergic reactions. Omalizumab was recently approved in adults and children greater than one year who are allergic to one or more foods for the prevention of serious allergic reactions in the setting of accidental exposure. Omalizumab also shows promise when combined with oral immunotherapy for possible allergen ingestion. Other classes of biologics and small molecule inhibitors have also demonstrated potential for use in preventing and treating food allergy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.iac.2024.07.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!